Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid.
5-Aminosalicylic acid (5-ASA) is an active ingredient of therapeutic agents used for Crohn's disease and ulcerative colitis. Because it is absorbed rapidly and extensively in the upper intestine, delivery of the agent specifically to the colon is necessary. We selected taurine as a colon-specific promoiety and designed 5-aminosalicyltaurine (5-ASA-Tau) as a new colon-specific prodrug of 5-aminosalicylic acid (5-ASA). It was expected that introduction of taurine would restrict the absorption of the prodrug and show additive effect to the anti-inflammatory action of 5-ASA after hydrolysis. 5-ASA-Tau was prepared in good yield by a simple synthetic route. The apparent partition coefficient of 5-ASA-Tau in 1-octanol/pH 6.8 phosphate buffer or CHCl3/pH 6.8 phosphate buffer was 0.10 or 0.18, respectively, at 37 degrees C. To determine the chemical and biochemical stability in the upper intestinal environment, 5-ASA-Tau was incubated in pH 1.2 and 6.8 buffer solutions, and with the homogenates of tissue and contents of stomach or small intestine of rats at 37 degrees C. 5-ASA was not detected from any of the incubation medium with no change in the concentration of 5-ASA-Tau. On incubation of 5-ASA-Tau with the cecal and colonic contents of rats, the fraction of the dose released as 5-ASA was 45% and 20%, respectively, in 8 h. Considering low partition coefficient and stability in the upper intestine, 5-ASA-Tau might be nonabsorbable and stable in the upper intestine. After oral administration, it would be delivered to the colon in intact form and release 5-ASA and taurine. These results suggested 5-ASA-Tau as a promising colon-specific prodrug of 5-ASA.
College of Pharmacy, Pusan National University, Pusan 609-735, Korea.
Yun Jin
YJ
Jung
Hak Hyun
HH
Kim
Hye Sik
HS
Kong
Young Mi
YM
Kim
D000284:Administration, Oral; D000636:Aminosalicylic Acids / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D000818:Animals; D002626:Chemistry, Pharmaceutical; D003106:Colon / Q000187:drug effects*; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D066298:In Vitro Techniques; D007408:Intestinal Absorption / Q000187:drug effects*; D019804:Mesalamine / Q000493:pharmacokinetics*; D009928:Organ Specificity / Q000187:drug effects*; D011355:Prodrugs / Q000493:pharmacokinetics*; D051381:Rats; D013654:Taurine / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000493:pharmacokinetics*
C479530:5-aminosalicyltaurine; D000636:Aminosalicylic Acids; D011355:Prodrugs; D013654:Taurine; D019804:Mesalamine